Nutrition Intervention Using an Eicosapentaenoic Acid (EPA)-containing Supplement in Patients with Advanced Colorectal Cancer. Effects on Nutritional and Inflammatory Status: a Phase II Trial

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2006 Oct 6

PMID 17021855

Citations 36

Authors

Jane A Read

Philip J Beale

Dianne H Volker

Narelle Smith

Annabel Childs

Stephen J Clarke

Affiliations

Soon will be listed here.

Abstract

Goals: The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy.

Materials And Methods: Patients with advanced CRC having one prior chemotherapy regimen received 480 ml of EPA-ONS daily for 3 weeks before commencing chemotherapy with folinic acid, 5-fluorouracil, irinotecan (FOLFIRI), and continued for 3 cycles of treatment (9 weeks). All assessments including weight, body composition, C-reactive protein (CRP), QOL, dietary intake, PPL and cytokine analyses were performed at baseline, 3 and 9 weeks.

Results: Twenty-three patients were enrolled, 20 completed 3 weeks, and 15 completed 9 weeks. The mean EPA-ONS intake was 1.7 tetrapaks (408 ml) daily. There was a significant increase in mean weight (2.5 kg) at 3 weeks (p=0.03). Lean body mass (LBM) was maintained. Protein and energy intake significantly decreased after the commencement of chemotherapy (protein p=0.003, energy p=0.02). There was a significant increase in energy levels (p=0.03), whilst all other QOL measures were maintained. PPL EPA levels increased significantly over the first 3 weeks. Mean CRP increased by 14.9 mg/L over the first 3 weeks (p=0.004), but decreased to baseline levels by the end of the trial. There was a significant correlation between plasma IL-6 and IL-10 concentrations and survival, and between IL-12 and toxicity.

Conclusion: Dietary counseling and the provision of EPA-ONS may result in maintenance of nutritional status and QOL, however randomized trials are required to evaluate the impact of EPA on toxicity from chemotherapy.

Citing Articles

Molecular Mechanisms Associated with the Inhibitory Role of Long Chain n-3 PUFA in Colorectal Cancer.

Jayathilake A, Luwor R, Nurgali K, Su X Integr Cancer Ther. 2024; 23:15347354241243024.

PMID: 38708673 PMC: 11072084. DOI: 10.1177/15347354241243024.

Fish Oil Supplementation Modifies the Proteome, Lipidome, and Function of High-Density Lipoprotein: Findings from a Trial in Young Healthy Adults.

Mueller P, Bergstrom P, Rosario S, Heard M, Pamir N J Nutr. 2024; 154(4):1130-1140.

PMID: 38237669 PMC: 11007744. DOI: 10.1016/j.tjnut.2024.01.007.

Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2....

Hull M, Loo Ow P, Ruddock S, Brend T, Smith A, Marshall H BMJ Open. 2023; 13(11):e077427.

PMID: 38030258 PMC: 10689403. DOI: 10.1136/bmjopen-2023-077427.

Synergistic Strategies for Gastrointestinal Cancer Care: Unveiling the Benefits of Immunonutrition and Microbiota Modulation.

Martinelli S, Lamminpaa I, Dubus E, Sarikaya D, Niccolai E Nutrients. 2023; 15(20).

PMID: 37892482 PMC: 10610426. DOI: 10.3390/nu15204408.

Anti-Inflammatory and Immune Properties of Polyunsaturated Fatty Acids (PUFAs) and Their Impact on Colorectal Cancer (CRC) Prevention and Treatment.

Tojjari A, Choucair K, Sadeghipour A, Saeed A, Saeed A Cancers (Basel). 2023; 15(17).

PMID: 37686570 PMC: 10487099. DOI: 10.3390/cancers15174294.

References

Meydani S . Modulation of cytokine production by dietary polyunsaturated fatty acids. Proc Soc Exp Biol Med. 1992; 200(2):189-93. DOI: 10.3181/00379727-200-43415. View

Andreyev H, Norman A, Oates J, Cunningham D . Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?. Eur J Cancer. 1998; 34(4):503-9. DOI: 10.1016/s0959-8049(97)10090-9. View

Crozier J, McKee R, McArdle C, Angerson W, Anderson J, Horgan P . The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006; 94(12):1833-6. PMC: 2361334. DOI: 10.1038/sj.bjc.6603185. View

Lukaski H, Bolonchuk W, Hall C, Siders W . Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol (1985). 1986; 60(4):1327-32. DOI: 10.1152/jappl.1986.60.4.1327. View

Ravasco P, Monteiro-Grillo I, Vidal P, Camilo M . Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 2005; 23(7):1431-8. DOI: 10.1200/JCO.2005.02.054. View

Ferrucci L, Cherubini A, Bandinelli S, Bartali B, Corsi A, Lauretani F . Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab. 2005; 91(2):439-46. DOI: 10.1210/jc.2005-1303. View

Nixon D, Kutner M, Heymsfield S, Foltz A, Carty C, Seitz S . Resting energy expenditure in lung and colon cancer. Metabolism. 1988; 37(11):1059-64. DOI: 10.1016/0026-0495(88)90068-6. View

Elia M, van Bokhorst-de van der Schueren M, Garvey J, Goedhart A, Lundholm K, Nitenberg G . Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. Int J Oncol. 2005; 28(1):5-23. DOI: 10.3892/ijo.28.1.5. View

Barber M, Ross J, Voss A, Tisdale M, Fearon K . The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999; 81(1):80-6. PMC: 2374349. DOI: 10.1038/sj.bjc.6690654. View

10.

Gibney M, Hunter B . The effects of short- and long-term supplementation with fish oil on the incorporation of n-3 polyunsaturated fatty acids into cells of the immune system in healthy volunteers. Eur J Clin Nutr. 1993; 47(4):255-9. View

11.

Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito M . Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine. 1999; 11(1):80-6. DOI: 10.1006/cyto.1998.0398. View

12.

Barber M, Ross J, Preston T, Shenkin A, Fearon K . Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr. 1999; 129(6):1120-5. DOI: 10.1093/jn/129.6.1120. View

13.

Evans W, Nixon D, Daly J, Ellenberg S, Gardner L, Wolfe E . A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol. 1987; 5(1):113-24. DOI: 10.1200/JCO.1987.5.1.113. View

14.

Moses A, Slater C, Preston T, Barber M, Fearon K . Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer. 2004; 90(5):996-1002. PMC: 2409623. DOI: 10.1038/sj.bjc.6601620. View

15.

Hardman W, Moyer M, Cameron I . Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer. 1999; 81(3):440-8. PMC: 2362926. DOI: 10.1038/sj.bjc.6690713. View

16.

Bauer J, Capra S . Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy--a pilot study. Support Care Cancer. 2004; 13(4):270-4. DOI: 10.1007/s00520-004-0746-7. View

17.

Endres S, Ghorbani R, Kelley V, Georgilis K, Lonnemann G, van der Meer J . The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989; 320(5):265-71. DOI: 10.1056/NEJM198902023200501. View

18.

Chung Y, Chang Y . Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003; 83(4):222-6. DOI: 10.1002/jso.10269. View

19.

Hardman W . Omega-3 fatty acids to augment cancer therapy. J Nutr. 2002; 132(11 Suppl):3508S-3512S. DOI: 10.1093/jn/132.11.3508S. View

20.

Meydani S, Endres S, Woods M, Goldin B, Soo C, Dinarello C . Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr. 1991; 121(4):547-55. DOI: 10.1093/jn/121.4.547. View